Reduced dose darunavir/ritonavir effective and safe for people switching while virally suppressed
Dolutegravir durable with high rates of viral suppression in people who experienced virological failure with older integrase inhibitors
Rilpivirine better tolerated, less toxic and more durable than efavirenz in first-line ART
NHS England saved £10 million by switching to generic anti-HIV drugs in 2016
Switching from abacavir to TAF improves platelet function
Failure of second-line ART is common in resource-limited countries, but modern third-line regimens work well
Biktarvy combo maintains viral suppression after switching therapy
Darunavir/ritonavir most durable boosted protease inhibitor in European patients, especially those switching treatment for any reason
Boosted protease inhibitor and lamivudine provides effective maintenance treatment
